Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

June 30, 2022

Conditions
Refractory Acute Myeloid LeukemiaRelapsed Acute Erythroid LeukemiaSalvage TreatmentHVA Regimen
Interventions
COMBINATION_PRODUCT

HVA Regimens as Salvage Treatment

venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Second People's Hospital

OTHER

collaborator

The Seventh Affiliated Hospital of Sun Yat-sen University

OTHER

collaborator

Maoming People's Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Shenzhen Hospital, Southern Medical University

UNKNOWN

collaborator

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

UNKNOWN

collaborator

The First People's Hospital of Chenzhou

UNKNOWN

collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT04424147 - Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | Biotech Hunter | Biotech Hunter